DNM1L and sarcopenia: However, expectations of all these inhibitors should be tempered by several recent findings, which show the narrow spectrum of physiologically viable Drp1 ranges in sarcopenia, and that overexpression or knockout of Drp1 typically contributes to aggravated sarcopenic phenotypes.69,141 Still, modulating DRP1/MFN2 shows strong preclinical efficacy and represents an active area for future translational research.114,140